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Abstract 
Data regarding the effects of progesterone and a progestagen on human normal breast epithelial cell proliferation 
and apoptosis are presented here. In postmenopausal women, adding progesterone to percutaneously 
administrated oestradiol significantly reduces the proliferation induced by oestradiol. In vitro and in 
premenopausal women, stopping the administration of nomegestrol acetate triggers a peak of apoptosis. Fibro-
adenoma and cancerous cells do not show this regulation of apoptosis. Progesterone seems to be important in 
normal breast homeostasis.  
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1. Effect of progesterone on breast epithelial cells proliferation 
Oestradiol, at physiological concentrations, is known to stimulate the proliferation of normal human breast 
epithelial cells, whereas the influence of progesterone has been debated for over 2 decades. Depending on the 
model used, the timing of progesterone administration and the method of evaluation used, progesterone is 
reported to stimulate, reduce or have no effect on the mitotic activity of breast epithelial cells. The model used 
here allowed us to delineate precisely the effects of progesterone, oestradiol alone or together on breast epithelial 
cell proliferation. 
1.1. Patients and methods 
40 postmenopausal women without hormonal replacement therapy received a hydroalcoholic gel containing 
oestradiol, progesterone, progesterone plus oestradiol, or placebo. Each gel formulation was applied on both 
breasts for 14 days prior to reduction mammoplasty or removal of a presumably benign lesion. 
A breast sample away from any lesion was fixed in formalin and used to quantitate the PCNA (proliferating cell 
nuclear antigen) expression. 
1.2. Results 
The proliferation index confirmed the absence of breast epithelial cell proliferation in postmenopausal women 
who did not receive hormone replacement therapy. Oestradiol induced growth of the terminal ductal lobular unit, 
whereas the proliferation index in the progesterone and combine progesterone plus oestradiol groups was not 
significantly different from that of untreated women. Our highly physiological model shows thus that adding 
progesterone to oestradiol significantly reduces the proliferation induced by oestradiol. 
2. Effects of NOMAC (nomegestrol) acetate on the apoptosis of breast epithelial cells in vitro and in vivo 
Apoptosis in the normal breast is a compensatory process that would lead to a reduction of the cell count in the 
same manner in which mitosis leads to an increase. In the 'resting' human breast, Ferguson and Anderson [1] 
observed a peak of apoptosis on day 28 of the menstrual cycle. This apoptosis would be triggered by the sudden 
decrease of the serum progesterone level seen 2 or 3 days before menstruation. 
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2.1. Materials and methods 
Normal human mammary epithelial cells cultures were obtained from reduction mammoplasties. Half of the 
cultures underwent a continuous treatment, and half underwent a withdrawal of NOMAC.  The control cultures 
received medium without steroids. 
In situ detection of apoptosis was performed by terminal dUTP nick-end labelling (TUNEL) method, which 
labels fragmented DNA. 
2.2. Results 
The cells unexposed to sex steroids and cells exposed continuously to NOMAC showed a low and constant level 
of apoptosis. On the contrary, human mammary epithelial cells which underwent withdrawal of NOMAC 
showed a peak of apoptosis after 24 to 30 h of withdrawal. These data were confirmed by measuring the caspase-
3 (the main enzyme implicated in apoptosis) activity in the culture lysates. The peak of apoptosis after NOMAC 
withdrawal was absent in T47D cancerous breast cells, suggesting that these tumoral cells have lost their 
endocrine regulation of apoptosis. 
2.3. Patients 
25 premenopausal women who asked for a reduction mammoplasty or undergoing removal of fibroadenoma 
applied to their breasts a hydroalcoholic gel containing NOMAC or placebo once a day, from days 1 to 14 of 
their menstrual cycle. Surgery was performed on day 15. Serum levels of progestins and oestradiol, tissue levels 
of PR (oestrogen receptor) and ER (oestradiol receptor), and tissue levels of oestradiol were similar in each 
group. Apoptosis was detected on breast sections using the TUNEL technique. 
2.4. Results 
The epithelial cells of normal breasts treated by NOMAC showed a significantly higher level of apoptosis 
compared with their placebo counterparts. In fibroadenomas, the rate of epithelial cells apoptosis was higher than 
in normal breasts, but did not vary accordingly to the breast exposure to progestin. 
Since the last application of gel was done about 24-30 h before surgery, it is likely that a decrease in the tissue 
level of NOMAC would be responsible for the induction of apoptosis in the normal breasts. Fibroadenoma 
epithelial cells did not respond to this stimulus. 
3. Conclusions 
Altogether, these data indicate that adding progesterone to oestradiol significantly reduces the proliferation 
induced by oestradiol. Exposure to synthetic progestins (and probably progesterone) in vitro and in vivo 
significantly increases the apoptosis rate of human mammary epithelial cells. Progesterone and progestins may 
prevent breast hyperplasia when used for 14 days per month at substitutive doses in cyclic treatment. 
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